Red Hot Rare Diseases and Europe’s record funding with Regina Hodits, Angelini Ventures | E63
Regina Hodits, who I have known for many years, spent 15 years at Wellington Partners...
Top 35 Biotech Startups to Watch in Europe
Europe’s next generation of biotech companies isn’t only coming from the usual hubs. We pulled...
MedinCell CEO on Long-Acting Drugs & France’s $1B Biotech Club | Christophe Douat | E62
Christophe has run MedinCell since 2009, when it was eight people in a converted garage....
Top 10 Biotech Exits in Europe Since 2023
Europe’s biotech M&A market has been on a tear. Since 2023, acquirers from MSD to...
Consumer Biotech’s Next Wave: Muscle, Sex, and Psychedelics
GLP-1 drugs have shown the world that blockbuster medicines don’t have to treat disease in...
Top 50 Investors in Biotech in 2026: Europe’s Most Active Life Sciences Funds
Who is writing the cheques that fund Europe’s next generation of medicines? Based on fund...
Billionaire wild bets on Consumer Biotech, GLP-1s, and psychedelics | Christian Angermayer | E61
Christian Angermayer became a multimillionaire before turning 25 thanks to the merger of Alnylam with...
ASCO 2026: ADC and In Vivo CAR-T Trends in Oncology
What are the biggest trends shaping oncology investment and drug development in 2026? We sat...
How Next-Generation Sequencing is Changing Biopharma Manufacturing
In the strictly regulated world of biopharmaceutical manufacturing, innovation faces a massive hurdle: the industry...
The $6 Billion Excel Illusion: Why Biotech Pipeline Forecasting is Broken (And How to Fix It)
If you sit in a Big Pharma boardroom during a pipeline review, you will inevitably...
